Rapt Therapeutics (RAPT)
(Delayed Data from NSDQ)
$4.40 USD
+0.07 (1.62%)
Updated May 13, 2024 04:00 PM ET
After-Market: $4.42 +0.02 (0.45%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RAPT 4.40 +0.07(1.62%)
Will RAPT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RAPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RAPT
Here's Why Rapt Therapeutics (RAPT) is Poised for a Turnaround After Losing -52.88% in 4 Weeks
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?
RAPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron
Biotech Stock Roundup: MRNA's Q4 Results, RAPT Down on Study Results & Other Updates
How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 90.48%
Other News for RAPT
RAPT falls for second day as Guggenheim, Barclays downgrade stock
Maintaining Hold Rating on RAPT Therapeutics Amid Clinical Uncertainties and Financial Outlook
Guggenheim downgrades Rapt Therapeutics on lack of clarity
Rapt Therapeutics just downgraded at Barclays, here's why
RAPT Therapeutics Inc. Reports Q1 2024 Earnings: A Detailed Financial Overview